- Home
- ENGN
ENGN
enGene Holdings Inc.
as 12-23-2024 4:00pm EST
Stocks
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
| Founded: | 1999 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 293.1M | IPO Year: | N/A |
| Target Price: | $29.78 | AVG Volume (30 days): | 205.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.42 - $18.40 | Next Earning Date: | 12-19-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest enGene Holdings Inc. News
ENGN Breaking Stock News: Dive into ENGN Ticker-Specific Updates for Smart Investing
Argus Research
16 hours ago
Daily – Vickers Top Insider Picks for 12/23/2024
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 12/20/2024
Business Wire
4 days ago
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
Argus Research
5 days ago
Daily – Vickers Top Insider Picks for 12/19/2024
Argus Research
6 days ago
Daily – Vickers Top Insider Picks for 12/18/2024
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 12/17/2024
Argus Research
8 days ago
Daily – Vickers Top Insider Picks for 12/16/2024
Argus Research
11 days ago
Daily – Vickers Top Insider Picks for 12/13/2024
Compare ENGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENGN enGene Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.